Bayer Inc. has announced that Health Canada has approved the marketing of Adempas (riociguat). Adempas is the first medicine indicated to treat adults with inoperable, or persistent /recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgery with World Health Organization Functional Class II or III pulmonary hypertension. For more details, go to: http://www.bayer.ca/files/News%20release%20Adempas%20CTEPH%202013%2009%2023%20FINAL.pdf